For example, activation of the proto-oncogenes MYC, ZNF217, and WT1 is associated with DEGs expressed by all three tumor types examined in this study (Fig 4), and therapeutic approaches to inhibition of all three in cancers are being developed [83–87]. The gene discussed is ZNF217; the disease is cancer.